Author

M. Surendran Nair

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:non-human primate· 1 Assay:protein sequence· 1

Frequent Co-Authors

A. Gontu· 2 shared R. H. Nissly· 2 shared S. V. Kuchipudi· 2 shared A. M. Minns· 1 shared B. Castillo· 1 shared C. Chen· 1 shared C. D. Maranas· 1 shared C. Herzog· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiophysics

A. Gontu

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A CNN model for predicting binding affinity changes between SARS-CoV-2 spike RBD variants and ACE2 homologues

C. Chen, V. S. Boorla, R. Chowdhury, R. H. Nissly, A. Gontu, S. K. Chothe, L. LaBella, P. Jakka, S. Ramasamy, K. J. Vandegrift, M. Surendran Nair, S. V. Kuchipudi, C. D. Maranas

The paper introduces a CNN model to predict RBD-hACE2 binding affinity changes for SARS-CoV-2 variants, achieving high accuracy and identifying variants with improved binding affinity.

bioRxiv · Mar 22, 2022 · PreprintBiophysics

Limited window for donation of convalescent plasma with high live-virus neutralizing antibodies for COVID-19 immunotherapy

A. Gontu, S. Srinivasan, E. Salazar, M. Surendran Nair, R. H. Nissly, D. Greenawalt, I. M. Bird, C. Herzog, M. J. Ferrari, I. Poojary, R. Katani, S. E. Lindner, A. M. Minns, R. Rossi, P. A. Christensen, , S. V. Kuchipudi

The study evaluates anti-SARS-CoV-2 antibody and neutralizing titer profiles in convalescent plasma samples to determine the optimal donation window for immunotherapy.

bioRxiv · Aug 21, 2020Immunology